Ramsay Générale de Santé SA (GDS.PA)
EUR 9.68
(1.89%)
EUR 9.68
(1.89%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 565.1 Million EUR | -5.81% |
| 2022 | 656.3 Million EUR | -6.83% |
| 2021 | 691 Million EUR | 6.2% |
| 2020 | 604 Million EUR | 14.71% |
| 2019 | 543.8 Million EUR | 65.49% |
| 2018 | 294.6 Million EUR | 30.11% |
| 2017 | 255.6 Million EUR | -7.16% |
| 2016 | 267.7 Million EUR | 9.17% |
| 2015 | 269.8 Million EUR | 22.0% |
| 2014 | 191.1 Million EUR | -29.6% |
| 2013 | 271.4 Million EUR | 22.75% |
| 2012 | 244.4 Million EUR | -34.31% |
| 2011 | 157.8 Million EUR | 38.01% |
| 2010 | 203 Million EUR | 12.19% |
| 2009 | 249.1 Million EUR | -15.23% |
| 2008 | 275.8 Million EUR | 11.98% |
| 2007 | 212.8 Million EUR | -40.52% |
| 2006 | 403.1 Million EUR | 127.78% |
| 2005 | 174.4 Million EUR | 17.59% |
| 2004 | 150 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | 86.75 Million EUR | -71.89% |
| 2023 Q3 | 271.1 Million EUR | -4.74% |
| 2023 FY | - EUR | -1.63% |
| 2023 Q4 | 120.5 Million EUR | -55.55% |
| 2023 Q2 | 284.6 Million EUR | 228.07% |
| 2022 Q2 | 312.7 Million EUR | 100.45% |
| 2022 FY | - EUR | -6.83% |
| 2022 Q4 | 308.6 Million EUR | 172.49% |
| 2022 Q3 | 113.25 Million EUR | -63.78% |
| 2022 Q1 | 156 Million EUR | -51.7% |
| 2021 Q4 | 323 Million EUR | 187.11% |
| 2021 FY | - EUR | 6.2% |
| 2021 Q1 | 171.5 Million EUR | -48.25% |
| 2021 Q2 | 335.4 Million EUR | 95.57% |
| 2021 Q3 | 112.5 Million EUR | -66.46% |
| 2020 Q4 | 331.4 Million EUR | 62.69% |
| 2020 FY | - EUR | 14.71% |
| 2020 Q3 | 203.7 Million EUR | -34.8% |
| 2020 Q2 | 312.4 Million EUR | 81.84% |
| 2020 Q1 | 171.8 Million EUR | -16.07% |
| 2019 Q1 | 136.45 Million EUR | -34.3% |
| 2019 Q2 | 272.9 Million EUR | 100.0% |
| 2019 Q3 | 177.45 Million EUR | -34.98% |
| 2019 Q4 | 204.7 Million EUR | 15.36% |
| 2019 FY | - EUR | 65.49% |
| 2018 FY | - EUR | 30.11% |
| 2018 Q4 | 207.7 Million EUR | 99.9% |
| 2018 Q3 | 103.9 Million EUR | 68.94% |
| 2018 Q2 | 61.5 Million EUR | 0.0% |
| 2018 Q1 | 61.5 Million EUR | -18.76% |
| 2017 Q4 | 75.7 Million EUR | 0.0% |
| 2017 Q3 | 75.7 Million EUR | 45.3% |
| 2017 Q1 | 52.1 Million EUR | -29.83% |
| 2017 Q2 | 52.1 Million EUR | 0.0% |
| 2017 FY | - EUR | -7.16% |
| 2016 Q3 | 74.25 Million EUR | 26.49% |
| 2016 Q2 | 58.7 Million EUR | 0.0% |
| 2016 FY | - EUR | 9.17% |
| 2016 Q1 | 58.7 Million EUR | -25.08% |
| 2016 Q4 | 74.25 Million EUR | 0.0% |
| 2015 Q1 | 56.55 Million EUR | 0.0% |
| 2015 FY | - EUR | 22.0% |
| 2015 Q2 | 56.55 Million EUR | 0.0% |
| 2015 Q3 | 78.35 Million EUR | 38.55% |
| 2015 Q4 | 78.35 Million EUR | 0.0% |
| 2014 FY | - EUR | -29.6% |
| 2014 Q2 | 40 Million EUR | -22.33% |
| 2014 Q1 | 51.5 Million EUR | -1.15% |
| 2013 Q3 | 71.8 Million EUR | -66.84% |
| 2013 Q1 | -55.7 Million EUR | -203.92% |
| 2013 Q2 | 216.5 Million EUR | 488.69% |
| 2013 FY | - EUR | 22.75% |
| 2013 Q4 | 52.1 Million EUR | -27.44% |
| 2012 FY | - EUR | -34.31% |
| 2012 Q4 | 53.6 Million EUR | -30.84% |
| 2012 Q3 | 77.5 Million EUR | 31.36% |
| 2012 Q2 | 59 Million EUR | 57.75% |
| 2012 Q1 | 37.4 Million EUR | -38.49% |
| 2011 Q3 | 79 Million EUR | -43.61% |
| 2011 Q4 | 60.8 Million EUR | -23.04% |
| 2011 Q2 | 140.1 Million EUR | 81.95% |
| 2011 FY | - EUR | 38.01% |
| 2011 Q1 | 77 Million EUR | 10.95% |
| 2010 FY | - EUR | 12.19% |
| 2010 Q1 | 28.5 Million EUR | -68.54% |
| 2010 Q2 | 64.7 Million EUR | 127.02% |
| 2010 Q3 | 77.4 Million EUR | 19.63% |
| 2010 Q4 | 69.4 Million EUR | -10.34% |
| 2009 Q2 | 67.5 Million EUR | 0.0% |
| 2009 FY | - EUR | -15.23% |
| 2009 Q4 | 90.6 Million EUR | 15.41% |
| 2009 Q3 | 78.5 Million EUR | 16.3% |
| 2008 FY | - EUR | 11.98% |
| 2007 FY | - EUR | -40.52% |
| 2006 FY | - EUR | 127.78% |
| 2005 FY | - EUR | 17.59% |
| 2004 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Clariane SE | 907.47 Million EUR | 37.729% |
| LNA Santé SA | 144.63 Million EUR | -290.708% |